Literature DB >> 33285522

Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.

Shaji K Kumar1, Natalie S Callander2, Kehinde Adekola3, Larry Anderson4, Muhamed Baljevic5, Erica Campagnaro6, Jorge J Castillo7, Jason C Chandler8, Caitlin Costello9, Yvonne Efebera10, Matthew Faiman11, Alfred Garfall12, Kelly Godby13, Jens Hillengass14, Leona Holmberg15, Myo Htut16, Carol Ann Huff17, Yubin Kang18, Malin Hultcrantz19, Sarah Larson20, Michaela Liedtke21, Thomas Martin22, James Omel23, Kenneth Shain24, Douglas Sborov25, Keith Stockerl-Goldstein26, Donna Weber27, Jennifer Keller28, Rashmi Kumar28.   

Abstract

Multiple myeloma is a malignant neoplasm of plasma cells that accumulate in bone marrow, leading to bone destruction and marrow failure. This manuscript discusses the management of patients with solitary plasmacytoma, smoldering multiple myeloma, and newly diagnosed multiple myeloma.

Entities:  

Year:  2020        PMID： 33285522     DOI： 10.6004/jnccn.2020.0057

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


  29 in total

Review 1.  [Benefits of radiotherapy for patients with solitary plasmacytoma or multiple myeloma].

Authors:  Laila König; Klaus Herfarth
Journal:  Radiologe       Date:  2021-11-11       Impact factor: 0.635

2.  Machine Learning-Based Overall Survival Prediction of Elderly Patients With Multiple Myeloma From Multicentre Real-Life Data.

Authors:  Li Bao; Yu-Tong Wang; Jun-Ling Zhuang; Ai-Jun Liu; Yu-Jun Dong; Bin Chu; Xiao-Huan Chen; Min-Qiu Lu; Lei Shi; Shan Gao; Li-Juan Fang; Qiu-Qing Xiang; Yue-Hua Ding
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 3.  Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.

Authors:  Shaji Kumar; Lawrence Baizer; Natalie S Callander; Sergio A Giralt; Jens Hillengass; Boris Freidlin; Antje Hoering; Paul G Richardson; Elena I Schwartz; Anthony Reiman; Suzanne Lentzsch; Philip L McCarthy; Sundar Jagannath; Andrew J Yee; Richard F Little; Noopur S Raje
Journal:  Blood Cancer J       Date:  2022-06-29       Impact factor: 9.812

Review 4.  Oncologist perspective: role of imaging in myeloma.

Authors:  Yael N Shapiro; Elizabeth K O'Donnell
Journal:  Skeletal Radiol       Date:  2021-07-17       Impact factor: 2.199

5.  Significant costs and low utilization of stored peripheral blood stem cells for salvage autologous transplant in multiple myeloma patients including those meeting mSMART criteria.

Authors:  Nausheen Ahmed; Lucy Li; Patricio Rojas; Fahrettin Covut; Jane Reese-Koc; Merle Kolk; Ehsan Malek; Leland Metheny; Timothy O'Brien; Paolo Caimi; Marcos de Lima; Brenda W Cooper
Journal:  Bone Marrow Transplant       Date:  2021-01-29       Impact factor: 5.483

6.  Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.

Authors:  Thierry Facon; Jesús San-Miguel; Meletios A Dimopoulos; Maria-Victoria Mateos; Michele Cavo; Sophie van Beekhuizen; Zijiao Yuan; João Mendes; Annette Lam; Jianming He; Eric Ammann; Shaji Kumar
Journal:  Adv Ther       Date:  2022-03-05       Impact factor: 4.070

7.  Case Report: Multiple Vertebral Compression Fractures in 14-Year-Old Children With Multiple Myeloma.

Authors:  Xia Wang; He He; Mei Zhang; Chuan Li; Chengyao Jia
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

8.  Different Patient Subgroup Different Maintenance, Proteasome Inhibitors or Immunomodulators Maintenance for Newly Diagnosed Multiple Myeloma: A 7-Year Single-Center Date in China.

Authors:  Xiaoyan Han; Chunxiang Jin; Gaofeng Zheng; Donghua He; Yi Zhao; Yi Li; Wenjun Wu; Weiyan Zheng; Guoqing Wei; Enfan Zhang; He Huang; Jingsong He; Zhen Cai
Journal:  Front Oncol       Date:  2021-06-14       Impact factor: 6.244

9.  The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience.

Authors:  Iuliana Vaxman; Eli Muchtar; Eapen Jacob; Prashant Kapoor; Shaji Kumar; Angela Dispenzieri; Francis Buadi; David Dingli; Wilson Gonsalves; Taxiarchis Kourelis; Rahma Warsame; Martha Lacy; William Hogan; Morie A Gertz
Journal:  Transplant Cell Ther       Date:  2021-06-18

10.  Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations.

Authors:  Yunhui Xiang; Liuyun Zhang; Pinpin Xiang; Juan Zhang
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.